In this week's video, Dr. Brian G.M. Durie the new oral proteasome inhibitor ixazomib.

Bottom Line:
It will be very good for patients if ixazomib is as valuable as currently available drugs.

Image of Dr. Brian G.M. DurieDr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.

Previous Post
#AskDrDurie: Can you help make sense of statistics?
Next Post
What to expect from this year’s ASH: a preview

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.